Merck Recalls Childhood Hib Vaccine Due to Ineffectiveness

Federal health officials alerted the public to a recall of specific lots of Merck's Haemophilus influenzae type b (Hib) vaccine. The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) jointly announced the action, citing a potential issue with the vaccine's effectiveness. Agency representatives detailed that potential issues were discovered during standard quality control testing.

According to the agencies, the recall affects particular lots of the Hib vaccine distributed by Merck. Health providers should immediately stop using any affected doses. The CDC published specific lot numbers subject to the recall on its website, allowing healthcare professionals to easily identify affected vaccines.

“We are asking providers to check their inventory and quarantine doses coming from these lots,” said Dr. Sarah Williams, a medical officer with the CDC. “Patient safety is our top priority.”

The Hib vaccine protects against Haemophilus influenzae type b, a bacteria that can cause severe infections, especially in young children. It can lead to illnesses such as meningitis, pneumonia, and epiglottitis. The CDC recommends Hib vaccination for all children starting at two months of age.

While acknowledging the potential concern, Dr. Williams emphasized the importance of continued vaccination. “We understand this recall may cause some anxiety,” Dr. Williams said. “The Hib vaccine remains a critical tool for protecting children from this dangerous disease. Catching up on other needed immunizations remains important.”

The agencies stated they are working with Merck to ensure an adequate supply of unaffected Hib vaccine to meet ongoing needs. The FDA is conducting its own assessment of the manufacturing process to determine the root cause of the ineffectiveness. Information regarding affected lot numbers and guidance for healthcare providers is available on the CDC website.